| U.S. Brand Names |
| Android®; Oreton® Methyl; Testred®; Virilon® |
 |
| Generic Available |
|
Yes |
|
| Pharmacological Index |
|
Androgen |
|
| Use |
|
Male: Hypogonadism; delayed puberty; impotence and climacteric symptoms Female: Palliative treatment of metastatic breast cancer; postpartum breast pain and/or engorgement |
|
| Restrictions |
|
C-III |
|
| Pregnancy Risk Factor |
|
X |
|
| Contraindications |
|
Hypersensitivity to methyltestosterone or any component, known or suspected carcinoma of the breast or the prostate, pregnancy |
|
| Warnings/Precautions |
|
Use with extreme caution in patients with liver or kidney disease or serious heart disease; may accelerate bone maturation without producing compensatory gain in linear growth |
|
| Adverse Reactions |
|
>10%: Cardiovascular: Edema Males: Virilism, priapism Females: Virilism, menstrual problems (amenorrhea), breast soreness Dermatologic: Acne 1% to 10%: Males: Prostatic hypertrophy, prostatic carcinoma, impotence, testicular Females: Hirsutism (increase in pubic hair growth) atrophy Gastrointestinal: GI irritation, nausea, vomiting Hepatic: Hepatic dysfunction <1%: Gynecomastia, amenorrhea, hypercalcemia, leukopenia, polycythemia, hepatic necrosis, cholestatic hepatitis, hypersensitivity reactions |
|
| Overdosage/Toxicology |
|
Abnormal liver function tests |
|
| Drug Interactions |
|
Decreased effect: Oral anticoagulant effect or decrease insulin requirements |
|
| Mechanism of Action |
|
Stimulates receptors in organs and tissues to promote growth and development of male sex organs and maintains secondary sex characteristics in androgen-deficient males |
|
| Pharmacodynamics/Kinetics |
|
Absorption: From GI tract and oral mucosa Metabolism: Hepatic Elimination: In urine |
|
| Usual Dosage |
|
Adults (buccal absorption produces twice the androgenic activity of oral tablets): Hypogonadism, male climacteric and impotence: Oral: 10-40 mg/day Androgen deficiency: Oral: 10-50 mg/day Buccal: 5-25 mg/day Postpubertal cryptorchidism: Oral: 30 mg/day Female: Breast pain/engorgement: Oral: 80 mg/day for 3-5 days Buccal: 40 mg/day for 3-5 days Breast cancer: Oral: 50-200 mg/day Buccal: 25-100 mg/day |
|
| Mental Health: Effects on Mental Status |
|
None reported |
|
| Mental Health: Effects on Psychiatric Treatment |
|
May cause leukopenia; use caution with clozapine and carbamazepine |
|
| Dental Health: Local Anesthetic/Vasoconstrictor Precautions |
|
No information available to require special precautions |
|
| Dental Health: Effects on Dental Treatment |
|
No effects or complications reported |
|
| Patient Information |
|
Take as directed; do not discontinue without consulting prescriber. Diabetics should monitor serum glucose closely and notify prescriber of changes; this medication can alter hypoglycemic requirements. You may experience acne, growth of body hair, loss of libido, impotence, or menstrual irregularity (usually reversible); nausea or vomiting (small frequent meals, frequent mouth care, sucking lozenges, or chewing gum may help). Report changes in menstrual pattern; deepening of voice or unusual growth of body hair; fluid retention (swelling of ankles, feet, or hands, difficulty breathing, or sudden weight gain); change in color of urine or stool; yellowing of eyes or skin; unusual bruising or bleeding; or other adverse reactions. Pregnancy/breast-feeding precautions: Inform prescriber if you are pregnant. Do not get pregnant during or for 1 month following therapy. Consult prescriber for instruction on appropriate contraceptive measures. This drug may cause severe fetal defects. Do not breast-feed. |
|
| Nursing Implications |
|
In prepubertal children, perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers |
|
| Dosage Forms |
|
Capsule: 10 mg Tablet: 10 mg, 25 mg Tablet, buccal: 5 mg, 10 mg |
|
|
Copyright © 2007 Drugs Area |
